Venture capital-backed RNA interference-based therapeutics developer Dicerna Pharmaceuticals has priced its IPO at $11 to $13 per share.
Jefferies, Leerink Partners, Stifel and Baird are acting as underwriters for the IPO, according to a document filed with the US Securities and Exchange Commission.
Dicerna will trade on the Nasdaq exchange under the symbol DRNA, the filing showed.
The company is backed by RA Capital, Brookside Capital, Deerfield, Omega Funds, Abingworth Management, Domain Associates, Oxford Bioscience Partners, Skyline Ventures and SR One.
Last August Dicerna raised $60m in an oversubscribed Series C round.
Copyright © 2014 AltAssets